Charles River Laboratories expands cell therapy manufacturing capacity

Blackholy/iStock via Getty Images

• Charles River Laboratories (NYSE:CRL) has expanded its cell therapy contract development and manufacturing facility in Memphis, Tenn.
• The company has added nine processing suites to the existing 16.
• The facility allows for the manufacture of clinical and commercial cell and gene-modified cell therapies.
• It previously received European Medicines Agency approval to commercially produce allogeneic cell therapy drug products.
• Read why Seeking Alpha contributor Seeking Profits has a sell rating on Charles River (CRL).